254 results
424B3
SEEL
Seelos Therapeutics Inc
15 Mar 24
Prospectus supplement
4:15pm
. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus … to April 2015, he held various roles of increasing
responsibility in finance and accounting at NPS Pharmaceuticals, Inc., a publicly-traded
S-8
EX-5.1
SEEL
Seelos Therapeutics Inc
6 Mar 24
Registration of securities for employees
5:38pm
other jurisdiction. We express no opinion concerning, and we assume no responsibility as to laws or judicial decisions related to, or any orders
8-K
EX-4.1
yiourw
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.2
osdnqo6kkrr5ao10t
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.1
hu6l8otq4p16w
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-5.1
fcwswxj2393
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
424B5
nfvh2j8 i4k2
30 Jan 24
Prospectus supplement for primary offering
6:05am
8-K
EX-5.1
6nwpqwn
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
8-K
EX-1.1
xyl9a6joth
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
8-K
EX-4.2
bb0tpzmq 3hcrf
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
8-K
EX-4.1
sn7np vqio89k
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
424B5
1d6xp
30 Nov 23
Prospectus supplement for primary offering
4:58pm